The logic of neoantigen-based immunotherapy rests on a simple biological distinction. Tumors accumulate mutations and aberrant RNA processing as they evolve, and some of these alterations generate peptide sequences that are absent from every healthy cell in the body. If those abnormal peptides are displayed on human leukocyte antigen molecules at the cell surface, the immune system can in principle recognize them as foreign. Most neoantigen vaccine efforts to date have focused on peptides presented by MHC class I molecules, which are seen by CD8-positive cytotoxic T cells. The Chinese-led team instead turned their attention to MHC class II presentation, the pathway that engages CD4-positive helper T cells. Helper T cells have historically been treated as supporting players in antitumor immunity, but a growing body of evidence suggests they can orchestrate potent, durable killing, particularly in tumors where class I presentation is weak.

Central to the study is the organoid technology that made the screening possible. Organoids are miniature, self-organizing three-dimensional tissue cultures grown from patient tumor cells, and they preserve much of the cellular and molecular architecture of the original malignancy far better than conventional two-dimensional cell lines. The researchers established hepatocellular carcinoma organoids alongside matched organoids derived from adjacent peritumoral tissue, giving them a paired system in which tumor-specific biology could be distinguished from background liver biology. They then built an organoid-immune cell co-culture model designed to test whether candidate antigens could provoke genuine cytotoxic activity against the tumor organoids themselves, rather than against simplified cell lines that may not reflect the antigen landscape of real tumors.

The discovery pipeline began with proteomic profiling. By comparing the peptide and protein content of tumor organoids with their matched peritumoral counterparts, the team catalogued peptides that were differentially expressed between malignant and healthy tissue. These candidates were then run through computational prediction tools, NetMHCIIpan and the Immune Epitope Database resource, to estimate how strongly each peptide would bind to HLA-DRB1, a common MHC class II molecule. From this ranked list, one candidate stood out: mITGB2, a peptide encoded by a splice variant of the ITGB2 gene. Splice variants arise when RNA is stitched together in an abnormal pattern, a process that is frequently deranged in cancer. The mITGB2 peptide combined high predicted HLA-DRB1 binding affinity with consistent overexpression in the tumor organoids, making it a prime immunogenic suspect.

Before committing to functional experiments, the investigators interrogated the clinical relevance of ITGB2 using data from The Cancer Genome Atlas and samples from their own patient cohort. The pattern that emerged was striking. High ITGB2 expression in hepatocellular carcinoma correlated with increased infiltration of CD4-positive T cells into the tumor and with a more favorable prognosis. This epidemiological signal suggested that ITGB2 is not merely a molecular curiosity but a biologically meaningful target, one that the immune system of at least some patients already notices and responds to. In tumors where antigen presentation is typically a bottleneck, a target that naturally attracts helper T cell traffic is an attractive candidate for therapeutic amplification.

The functional validation proceeded in two stages, in vitro and in vivo. In the laboratory phase, the team loaded dendritic cells, the professional antigen-presenting cells of the immune system, with lysates prepared from the tumor organoids. When these loaded dendritic cells were co-cultured with peripheral blood mononuclear cells, they activated the PBMCs and induced cytotoxicity that was specifically directed against the HCC organoids. Proteomic analysis of this process revealed upregulation of HLA-DRB1, indicating that the co-culture system enhanced antigen presentation capacity, exactly the bottleneck the researchers had set out to relieve. When dendritic cells were instead loaded with the mITGB2 peptide itself, they promoted the polarization of CD4-positive T cells toward the Th1 lineage, the helper subset characterized by inflammatory signaling and strong antitumor activity.

The in vivo stage brought the work into humanized mouse models of hepatocellular carcinoma, animals engineered to carry a functional human immune system so that human-specific immune interactions could be studied. In these models, treatment with mITGB2-loaded dendritic cells suppressed tumor growth. This result is the critical proof of concept for the entire pipeline: a neoantigen discovered through organoid-based proteomics and computational prediction could be formulated into a cellular therapy and elicit measurable tumor control in a living system that approximates human immunology. The authors report that mITGB2 behaved as a functionally immunogenic, MHC class II-restricted neoantigen, a designation that few candidate antigens earn after passing through such a demanding gauntlet of validation.

The broader significance of the study lies in its platform design as much as in the specific target it uncovered. Neoantigen discovery has often depended on genomic sequencing and prediction algorithms alone, an approach that generates long lists of candidates with uncertain immunogenicity and high failure rates in the clinic. By anchoring the search in patient-derived organoids, the Sichuan team ensured that every candidate was drawn from the actual proteomic output of living tumor tissue, and by testing candidates in organoid-immune co-cultures, they filtered for peptides that could genuinely provoke cytotoxic responses rather than merely binding predictions on a computer screen. This workflow, from paired organoid proteomics through HLA binding prediction to functional co-culture and finally humanized animal testing, offers a template that could in principle be applied to other tumor types where antigen presentation and T cell dysfunction limit immunotherapy.

There are, of course, substantial distances between a preclinical result and a licensed medicine. The study was conducted under ethical approval from Sichuan Cancer Hospital with written informed consent from all participants, and the authors declare no conflicts of interest, but the findings remain at the stage of laboratory and animal models. Questions about manufacturing consistency, patient selection, HLA-DRB1 coverage across diverse populations, and the durability of the Th1 response in humans will all need to be answered in future translational work. Nevertheless, the identification of mITGB2 gives the field something concrete: a validated MHC class II-restricted target in a cancer that badly needs new immunotherapeutic options, and a screening platform that produced it. As neoantigen vaccine development matures, approaches that honor the full complexity of the tumor microenvironment, as organoids do, may prove to be the difference between candidates that look promising on paper and therapies that actually work in patients.

Subject of Research: Identification of the MHC class II neoantigen mITGB2 in hepatocellular carcinoma using an organoid-based screening platform

Article Title: Identification of mITGB2 as an MHC-II neoantigen using hepatocellular carcinoma organoids

Article References: Zhong, D., Chen, Y., Ren, Y., Zou, H., Huang, Y., Shi, Y., Yan, H., Huang, X., Yang, Q., & Shang, J. (2026). Identification of mITGB2 as an MHC-II neoantigen using hepatocellular carcinoma organoids. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04542-5

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04542-5

Keywords: neoantigen, hepatocellular carcinoma, organoids, MHC class II, ITGB2, CD4 T cells, Th1 polarization, dendritic cells, cancer immunotherapy, HLA-DRB1, splice variant, humanized mouse models